A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Phase 1/2 Terminated
50 enrolled
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
227 enrolled
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled 43 charts
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Phase 1 Terminated
4 enrolled
A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
Phase 1 Terminated
11 enrolled
PORTSIDE
Phase 2 Terminated
38 enrolled
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
Phase 1 Terminated
29 enrolled
Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®
Phase 3 Terminated
52 enrolled
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Phase 1 Terminated
10 enrolled
Tamarack
Phase 2 Terminated
192 enrolled 20 charts
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
Phase 1/2 Terminated
46 enrolled 22 charts
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
45 enrolled 44 charts
RELATIVITY-098
Phase 3 Terminated
1,093 enrolled 15 charts
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
Phase 2 Terminated
3 enrolled 7 charts
KZR-261 in Subjects With Advanced Solid Malignancies
Phase 1 Terminated
61 enrolled 25 charts
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Phase 1/2 Terminated
31 enrolled
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Phase 1 Terminated
17 enrolled
A Study of ASP1012 in Adults With Solid Tumors
Phase 1 Terminated
15 enrolled
PAVO
Phase 2 Terminated
22 enrolled 17 charts
MAVIS
Phase 3 Terminated
504 enrolled 23 charts
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Phase 1 Terminated
65 enrolled 52 charts
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
Phase 1/2 Terminated
31 enrolled 12 charts
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
31 enrolled
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Phase 2 Terminated
23 enrolled 15 charts
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
Phase 1 Terminated
75 enrolled
COMBI-i
Phase 3 Terminated
568 enrolled 28 charts
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Phase 1 Terminated
9 enrolled
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
Phase 2/3 Terminated
20 enrolled 18 charts
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Phase 1 Terminated
88 enrolled
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
Phase 1 Terminated
44 enrolled
MGC018 With or Without MGA012 in Advanced Solid Tumors
Phase 1/2 Terminated
143 enrolled 33 charts
Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma
Phase 3 Terminated
393 enrolled
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
11 enrolled
A Study to Investigate LYL845 in Adults With Solid Tumors
Phase 1 Terminated
39 enrolled
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Phase 1 Terminated
20 enrolled
CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
Phase 2 Terminated
44 enrolled 19 charts
ARTISTRY-6
Phase 2 Terminated
173 enrolled
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
Phase 2 Terminated
11 enrolled 8 charts
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Phase 1 Terminated
60 enrolled
RAPTOR
Phase 1 Terminated
27 enrolled
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Phase 1 Terminated
241 enrolled
A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma
Phase 1 Terminated
22 enrolled
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Phase 1/2 Terminated
222 enrolled 49 charts
Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma
Phase 1 Terminated
7 enrolled
Study of INCB086550 in Select Solid Tumors
Phase 2 Terminated
16 enrolled 17 charts
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Phase 2 Terminated
205 enrolled 54 charts
STARLING
Phase 1 Terminated
31 enrolled
ATL001 in Patients With Metastatic or Recurrent Melanoma
Phase 1/2 Terminated
13 enrolled 14 charts
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
Phase 1 Terminated
8 enrolled